Abstract
Interferon (IFN) has captured the imagination of the virologic community (and only more recently those concerned with cancer therapy), since its discovery in 1957. However, the lack of adequate quantities of high purity IFN has hampered basic research on the biology of IFN as well as the conduct of clinical trials to determine IFN’s practical efficacy. Both problems — quantity and purity — have been addressed and solved by the application of recombinant DNA (rDNA) technology to IFN production. In addition to allowing the production of pure IFN in copious quantity, experimental use of cloned IFN genes has generated fundamental information which has radically altered our conception of IFN’s physiologic role and has explained apparent contradictions within the literature.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
